Key statistics
As of last trade, Annovis Bio Inc (07X:STU) traded at 7.31, 65.38% above the 52 week low of 4.42 set on May 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.48 |
---|---|
High | 7.48 |
Low | 7.31 |
Bid | 7.17 |
Offer | 7.44 |
Previous close | 7.40 |
Average volume | 0.00 |
---|---|
Shares outstanding | 13.05m |
Free float | 10.24m |
P/E (TTM) | -- |
Market cap | 105.08m USD |
EPS (TTM) | -4.42 USD |
Data delayed at least 15 minutes, as of Oct 09 2024.
More ▼
Announcements
- Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
- Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
- Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
- Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Annovis Bio Reports Second Quarter Financial Results and Provides Business Update
- Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
- Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
- Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
- Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
- Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
More ▼